NASDAQ:GILD Gilead Sciences Q3 2026 Earnings Report $147.74 -1.31 (-0.88%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Gilead Sciences EPS ResultsActual EPSN/AConsensus EPS $2.12Beat/MissN/AOne Year Ago EPSN/AGilead Sciences Revenue ResultsActual RevenueN/AExpected Revenue$7.77 billionBeat/MissN/AYoY Revenue GrowthN/AGilead Sciences Announcement DetailsQuarterQ3 2026Date10/29/2026TimeAfter Market ClosesConference Call DateThursday, October 29, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Gilead Sciences Earnings HeadlinesGilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on ItOctober 1 at 9:38 AM | finance.yahoo.comGilead Sciences (GILD) Declines More Than Market: Some Information for InvestorsSeptember 30 at 7:13 PM | finance.yahoo.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 1 at 1:00 AM | Investors Alley (Ad)Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of DirectorsSeptember 29 at 2:23 PM | finance.yahoo.comCan Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?September 28 at 8:50 PM | insidermonkey.comGilead vs. Danaher: Which Healthcare Growth Story is More Convincing?September 28 at 7:57 PM | finance.yahoo.comSee More Gilead Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gilead Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gilead Sciences and other key companies, straight to your email. Email Address About Gilead SciencesGilead Sciences (NASDAQ:GILD) (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need. Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients. Through its Kite subsidiary, the company also develops and provides cell therapies, including Yescarta and Tecartus, while Trodelvy is an antibody-drug conjugate used in the treatment of certain cancers. Founded in 1987, Gilead is headquartered in Foster City, California, and serves patients and healthcare providers in the United States and international markets. The company operates research, manufacturing and commercial activities globally and is led by Chairman and Chief Executive Officer Daniel O’Day.View Gilead Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
